Every 10-Q that Organogenesis Holdings Inc. (ORGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ORGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGO filings page.
Organogenesis Holdings Inc. reported sharply weaker results for the quarter ended June 30, 2026. Total revenue was $ 43,755 (amounts in thousands), down from $ 101,005 a year earlier, as net product revenue fell 58% to $ 79,055 for the first six months, driven mainly by disruption from U.S. Medicare reimbursement changes and confusion following withdrawn LCDs and CMS comments on discarded product.
The company posted a quarterly net loss of $ 96,267 and year-to-date net loss of $ 149,423 (amounts in thousands), with loss per share of $ 0.77 for the quarter and $ 1.21 year-to-date. A full valuation allowance against deferred tax assets generated income tax expense of $ 30,070 (amounts in thousands) for the first half. Management undertook significant restructuring, closing a St. Petersburg facility and reducing headcount by about 226 employees, recording $ 8,781 and $ 5,099 (amounts in thousands) of restructuring charges plus $ 5,588 of R&D program termination costs. Cash and cash equivalents were $ 46,097 with working capital of $ 139.7 million; the company expects these resources and cash from sales to fund operations for at least 12 months beyond the report date. The FDA accepted the Biologics License Application for ReNu with a PDUFA target action date of April 24, 2027, while the planned Dermagraft relaunch has been delayed with no current timing projection.
Organogenesis Holdings Inc. reported a sharp downturn for the quarter ended March 31, 2026. Net product revenue fell to $36.3 million from $86.7 million, driven mainly by a steep decline in Advanced Wound Care sales linked to Medicare reimbursement changes and clinician confusion.
Total revenue was $37.2 million, while the company posted a net loss of $53.2 million versus $18.8 million a year earlier, with gross profit compressing significantly. Adjusted EBITDA worsened to a loss of $48.2 million, reflecting lower volume, pricing pressure, inventory write-downs and restructuring costs.
The company implemented a March 2026 restructuring, closing its St. Petersburg, Florida facility and reducing headcount by about 10%, recording $8.8 million of related charges. Despite losses, Organogenesis ended the quarter with $91.4 million in cash and access to a $75.0 million undrawn revolving credit facility, and continues investing in its Smithfield, Rhode Island biomanufacturing build-out and ReNu biologics license application.
Organogenesis Holdings Inc. reported Q3 2025 results showing stronger profitability. Total revenue was $150.864M (net product revenue $150.487M), up from $115.177M a year ago. Income from operations rose to $20.727M, and net income reached $21.567M, or $0.11 per diluted share. Advanced Wound Care drove the quarter with $141.451M, while Surgical & Sports Medicine contributed $9.036M.
Year to date, revenue was $338.562M versus $355.387M in 2024, with a net loss of $6.668M. Cash and cash equivalents were $63.745M and operating cash flow was an outflow of $49.729M for the nine months. Accounts receivable increased to $168.783M and inventories to $39.583M. The company recorded $0.603M of grant income tied to the Smithfield facility buildout and ended the quarter with deferred grant income on the balance sheet.
The revolving credit facility was reduced to $75M with updated covenants; there were no outstanding borrowings. Management flagged potential Medicare LCD changes effective January 1, 2026 that would limit coverage for several products. In clinical updates, a second Phase 3 ReNu knee OA trial did not meet its primary endpoint; an FDA meeting is scheduled for December 12, 2025 to discuss a BLA using combined data.